HK1198133A1 - Crizotinib for use in the treatment of cancer - Google Patents

Crizotinib for use in the treatment of cancer

Info

Publication number
HK1198133A1
HK1198133A1 HK14111675.3A HK14111675A HK1198133A1 HK 1198133 A1 HK1198133 A1 HK 1198133A1 HK 14111675 A HK14111675 A HK 14111675A HK 1198133 A1 HK1198133 A1 HK 1198133A1
Authority
HK
Hong Kong
Prior art keywords
crizotinib
cancer
treatment
Prior art date
Application number
HK14111675.3A
Other languages
English (en)
Chinese (zh)
Inventor
．克里斯滕森
鄒亞紅
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198133A1 publication Critical patent/HK1198133A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK14111675.3A 2011-08-02 2014-11-19 Crizotinib for use in the treatment of cancer HK1198133A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161514386P 2011-08-02 2011-08-02
PCT/IB2012/053765 WO2013017989A1 (fr) 2011-08-02 2012-07-24 Crizotinib pour l'utlisation dans le traitement de cancer

Publications (1)

Publication Number Publication Date
HK1198133A1 true HK1198133A1 (en) 2015-03-13

Family

ID=46845786

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111675.3A HK1198133A1 (en) 2011-08-02 2014-11-19 Crizotinib for use in the treatment of cancer

Country Status (15)

Country Link
US (1) US20160206608A1 (fr)
EP (1) EP2739284A1 (fr)
JP (1) JP2013032355A (fr)
KR (1) KR20140041906A (fr)
CN (1) CN103841972A (fr)
AR (1) AR087731A1 (fr)
AU (1) AU2012291744A1 (fr)
BR (1) BR112014002141A2 (fr)
CA (1) CA2842493A1 (fr)
HK (1) HK1198133A1 (fr)
IL (1) IL230698A0 (fr)
MX (1) MX2014001354A (fr)
RU (1) RU2014102935A (fr)
TW (1) TW201313698A (fr)
WO (1) WO2013017989A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
DK2881402T3 (en) 2009-02-12 2017-08-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
CA2872645A1 (fr) 2012-05-30 2013-12-05 Nippon Shinyaku Co., Ltd. Derive heterocyclique aromatique et produit pharmaceutique
EP2764866A1 (fr) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
ITMI20131124A1 (it) 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
KR101538385B1 (ko) * 2013-09-02 2015-07-29 가톨릭대학교 산학협력단 크리조티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물
EA032255B1 (ru) * 2014-03-27 2019-04-30 Янссен Фармацевтика Нв ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-a][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Ros1
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
IL292302B2 (en) 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy
US20220033402A1 (en) * 2018-09-27 2022-02-03 Dana-Farber Cancer Institute, Inc. Macrocyclic inhibitors of alk, trka, trkb, and ros1
CN115003307A (zh) 2020-02-06 2022-09-02 伟迈可生物有限公司 用于预防或治疗与kras突变相关的癌症的药物组合物
EP4115887A1 (fr) 2020-03-03 2023-01-11 Wellmarker Bio Co., Ltd. Composition pharmaceutique pour la prévention ou le traitement du cancer présentant une mutation kras et l'activation de ron
WO2021196655A1 (fr) * 2020-04-03 2021-10-07 中国药科大学 Composé contenant une structure benzimidazole, son procédé de préparation et application de celui-ci
CN113493437B (zh) * 2020-04-03 2022-07-26 中国药科大学 含苯并咪唑结构的化合物及其制备方法和用途
CN111518769A (zh) * 2020-05-13 2020-08-11 四川大学华西医院 一种克唑替尼获得性耐药肺腺癌细胞系的建立方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Liberation amelioree d'agents medicamenteux actifs par un enrobage de chewing-gum
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
OA13151A (en) 2003-02-26 2006-12-13 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors.
EA011725B1 (ru) * 2004-08-26 2009-04-28 Пфайзер Инк. Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
ME01788B (me) 2004-08-26 2011-02-28 Pfizer Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
DK2671954T3 (en) 2006-01-20 2018-08-13 Cell Signaling Technology Inc Translocation and mutant ROS kinase in human non-small cell lung carcinoma
AU2008314567B2 (en) 2007-10-18 2014-11-20 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
DK2881402T3 (en) 2009-02-12 2017-08-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer

Also Published As

Publication number Publication date
RU2014102935A (ru) 2015-09-10
MX2014001354A (es) 2014-10-14
AR087731A1 (es) 2014-04-16
WO2013017989A1 (fr) 2013-02-07
EP2739284A1 (fr) 2014-06-11
TW201313698A (zh) 2013-04-01
JP2013032355A (ja) 2013-02-14
US20160206608A1 (en) 2016-07-21
CA2842493A1 (fr) 2013-02-07
CN103841972A (zh) 2014-06-04
BR112014002141A2 (pt) 2017-02-21
AU2012291744A1 (en) 2014-02-20
IL230698A0 (en) 2014-03-31
KR20140041906A (ko) 2014-04-04

Similar Documents

Publication Publication Date Title
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
HK1198133A1 (en) Crizotinib for use in the treatment of cancer
HK1192758A1 (zh) '- 用於治療癌症的 -氟- '-脱氧尿苷的氨基磷酸酯衍生物
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
ZA201603332B (en) Gla monotherapy for use in cancer treatment
IL229474A0 (en) Cannabinoids for use in the treatment of neuropathic pain
IL239007B (en) Eribulin for use in the treatment of breast cancer
IL238116B (en) A process for preparing compounds for use in the treatment of cancer
PL2780332T3 (pl) Morfolinylobenzotriazyny do zastosowania w terapii rakowej
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
EP2744786A4 (fr) 2-imidazolidinones et 2-imidazolones substituées et leur utilisation dans le traitement du cancer
HK1199729A1 (en) Aldh-2 inhibitors in the treatment of addiction aldh-2
PL2769727T3 (pl) Kombinacja deoksynukleozydu/nukleozydu do stosowania w leczeniu nowotworów
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
EP2709623A4 (fr) Médicaments et procédés pour traiter le cancer
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
AU2012900259A0 (en) Agents for use in cancer therapy
EP3104863C0 (fr) Salicylates pour l'utilisation dans le traitement du cancer